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We read the recent paper by U. Persson and colleagues with interest [1]. However, we think the paper contained some misunderstandings which we believe should be discussed further as this paper is likely to be widely read both in Sweden and across Europe.

We were concerned with the comments made about cost/ QALY cut-off levels in Sweden since we found in 2008 (Wettermark, Godman et al) [2] and 2009 (Godman, Wettermark et al) [3], that the TLV has not established cost/ QALY cut-off levels. Moreover, the TLV maintained that there should be various levels for different diseases. In addition, the TLV were concerned that companies would play the system if they knew the level in advance and any limit would need re-adjusting with inflation [2,3].  This was endorsed in the reference provided by U. Persson et al (Reference 19 - Hugosson and Engstrom). In the reference, Hugosson and Engstrom stated ‘No explicit value or threshold exists’ [4]. They also analysed TLV decisions between October 2002 and 2007, and demonstrated there was a correlation between disease severity and willingness to pay. Overall, the QALY averaged €35,000 for reimbursed drugs, rising to approximately €100,000 for severe diseases [4]. Hugosson and Engstrom subsequently concluded the TLV had ‘not established a threshold value for the QALY’, exacerbated by the low number of rejections during this period [4]. 

We were surprised by the comment that the number of products not reimbursed by the TLV averaged 20% in the past 9 years. This is because published sources revealed that between October 2002 and March 2005, TLV denied reimbursement for 13 out of 107 drug applications [3, 5, 6]. Moise and Docteur from the OECD concluded that during this period ‘rejecting a pharmaceutical for reimbursement because the price is too high is a rare occurrence’ [6]. In 2006, 10% of new chemical entities (4 out of 40 products) were not approved for reimbursement [2,3], and in 2007 five new applications (10%) were denied reimbursement [2,3]. These findings appear to confirm the comments of Hugosson and Engstrom [4]. Between 2009 and 2011, this increased to an average of 17% of new drug applications denied reimbursement (2011: 4/27 products, 2010: 2/44 products and in 2009: 11/30 products – F. Nilsson Personal Communication]. This is particularly important since the higher the percentage of new premium priced products granted reimbursement by the TLV, the greater the pressure on county council resources.

We were also surprised by comments by Persson et al that Value Based Pricing (VBP) is rare for products in the healthcare market. It may be that not all countries use cost/ QALYs in their decision making; however, a number of European countries do apply some form of ‘value based’ approach to potential prices when considering reimbursement for new innovative products. For instance in Austria, a maximum reimbursed price of 10% above current standards is granted for those new products that are evaluated as having ‘added benefit’ [7]. This rises to an average price among targeted European countries for new products that are evaluated as having ‘substantial benefit’ over existing standards, provided the price can be justified by a pharmacoeconomic evaluation [7]. In France, the reimbursed price for new products is directly related to their perceived benefit versus current standards (ASMR rating) [8], and in Germany there are direct price negotiations for new products with additional benefit between the manufacturers and the Sickness Funds (payers of healthcare) [9]. This is based on the perceived level of health gain versus current standard treatments; divided into substantial, considerable or small – mirroring the situation in France [9]. Recommendations for reimbursing new products in Norway are principally based on cost/ QALY considerations [10], and reimbursement considerations for new products in Poland now include an economic analysis (CEA/ CUA) combined with a budget impact analysis [11]. Reimbursed prices for new innovative products in Croatia, i.e. those outside of current reference price classes, are now based on their average price in France, Italy and Slovenia, reflecting their willingness to reward innovation with higher prices [12]. 

We agree with the suggestions of Persson et al concerning the need for horizon scanning activities and, in fact, these have been ongoing among some of the counties in Sweden for some time [13]. Horizon scanning activities are now growing across Sweden in a coordinated manner between the counties, and in some counties these activities are combined with forecasting of future drug use alongside an estimate of total expenditure by product class [13]. The objective is to improve budget planning for new drugs in patient populations where they are perceived to provide most value [13]. As part of the process, new generics are identified to release resources to fund new drugs within pertinent or other disease areas [13]. This is facilitated by the price of generics in Sweden as low as 4 to 13% of pre-patent loss prices [3], which will fall further with the introduction of monthly auctions for generics [14]. This mirrors the low prices of generics among other European countries, irrespective of the size of their populations [15-19]. Without these combined activities, countries will struggle to fund new drugs. This is already happening [20,21], and is not in the best interest of any key stakeholder group.

The low prices for generics suggest that there is the potential for pharmaceutical companies to realize appreciable profits for their new drugs, and hence innovation is rewarded. Current rewards would be greater if pharmaceutical companies did not spend considerable resources on marketing activities to physicians. For instance, in 2004 pharmaceutical companies spent US$53 billion promoting their products to physicians in the US [22]. This alone was enough to fund the development of 40 to 50 new chemical entities, based on the figures provided by Persson et al. 

We recognise the suggestion by Persson et al that health authorities should take into consideration the price of the drug throughout its lifecycle. However, we consider this view ignores the concept of opportunity costs with yearly budgets, exacerbated by changing demographics and the current financial crisis in Europe.

We do not agree with the comments of Persson et al that the goal of the counties is cost containment. There are both ongoing horizon scanning activities as well as forecasting activities of future drug use, based on their perceive added value, to improve budget planning. This includes the TNF inhibitors, which are now among the highest expenditure drugs within the counties in Sweden. The focus on TNF alpha drugs has increased with many standard drugs used to treat conditions in ambulatory care losing their patents in recent years. These include drugs to treat acid-related disorders, coagulation disorders, congestive heart failure, diabetes depression, hypercholesterolaemia, hypertension (including now the angiotensin receptor blockers), and schizophrenia. Funding for new premium priced drugs is facilitated by the extensive range of demand-side measures instigated within the counties to encourage the prescribing of generics in a class/ related class where all products are seen as essentially similar to conserve resources [3, 23,24]. Without these efforts, expenditure on for instance the proton pump inhibitors and statins would be up to ten times greater in Sweden without enhancing care, comparable to countries with limited demand-side measures to counter-act commercial influences [23,25]. As a result, reducing available funds for new innovative products. 

The comments by Persson et al that counties are only focusing on cost containment also ignores the development and implementation of formularies of essential drugs among the counties in Sweden including the ‘Wise List’ in Stockholm county council [3]. The ‘Wise List’ in Stockholm was designed, developed and implemented to enhance the knowledge of drugs among prescribers and the public. The objective being to improve the quality, consistency and efficiency of prescribing [3,26]. The ‘Wise List’ concept is built on providing physicians clear guidance on which drugs to prescribe for the vast majority of diseases in ambulatory care, based on available evidence, and involving experts and prescribers in the region [26]. Key criteria for product selection include the efficacy and safety of the drugs to treat given diseases in accordance with Evidence Based principles, as well as their efficiency [3,26]. Physicians trust the guidance as demonstrated by the high and growing adherence rates – at approximately 80% of all prescriptions in ambulatory care [26]. Östergotland has also established programmes to attain quality assurance and prescribing efficiency among its Primary Healthcare Centres [3]. Physicians have to justify their prescribing performance to the county as well as members of the public if they wish to realise any savings through increased efficiency [3].   

In view of the growing resource pressures among the counties, exacerbated by the fact that the TLV does not currently appraise hospital only products which can be expensive, we also believe it is difficult to discuss prescribing levels for the TNF alpha inhibitors as well as trastuzumab in isolation without discussing opportunity costs. This includes likely treatments that will be forgone if there was increased prescribing of these products [27]. Treatments forgone could have included those with greater prescribing efficiency, especially with the growing number of standard treatments now available as low cost generics [28]. However, we recognise it is difficult to discuss this without critically looking at all current county council prescribing habits and their rationale.

Finally, we consider the concept of introducing national or regional rebates, discounts or free drugs into the system in Sweden to enhance the value of new drugs is not new. It may, however, be new to Sweden. Patient access schemes either nationally or regionally have been ongoing among European countries for some time to enhance the value of new drugs, and hence their potential for reimbursement [29-32, J Lonsdale Personal Communication]. There is no reason why such arrangements should not be considered for Sweden if this helps enhance funding for new drugs, and the schemes are critically evaluated to ensure they follow evidence based principles. This requires consultations with trusted pharmacotherapeutic experts and clinical pharmacologists working in county council Drug and Therapeutic Committees. However, there are occasions when authorities nationally and regionally instigate further restrictions over and above those of the product licence or reimbursement agencies due to concerns with patient safety once launched. This was been seen with extensive county pre- and post-launch activities with dabigatran, which has inherent dosage and safety problems in the elderly [9]. We believe such activities should be acknowledged to improve the subsequent care of patients, and potentially help preserve new products on the market when they are used in a much wider population than those in the randomised controlled clinical trials undertaken for registration. Already, we are seeing cases of excessive bleeding and deaths with dabigatran when used in a wider more elderly population, endorsing the approaches among the counties in Sweden [9,33].

We are looking forward to the response from the authors.

Dr Brian Godman
Professor Lars L Gustafsson
Division of Clinical Pharmacology
Department of Laboratory Medicine
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